Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 3/20 | 0.79 |
| ▸ | HTR3A | P46098 | 1/20 | 0.79 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 14/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5780083 | 0.88 | HTR4 (1.00) | HTR4HTR3AKCNH2CHRM1CHRM2 | |
| Hydrochloric Acid SCHEMBL5889662 | 0.87 | HTR4 (0.98) | HTR4HTR3AKCNH2CHRM1CHRM2 | |
| SCHEMBL7240727 | 0.87 | KCNH2 (0.60) | HTR4HTR3AKCNH2 | |
| SCHEMBL5889439 | 0.85 | KCNH2 (0.61) | HTR4HTR3AKCNH2 | |
| SCHEMBL5889899 | 0.84 | KCNH2 (0.62) | HTR4HTR3AKCNH2 | |
| SCHEMBL6767167 | 0.84 | KCNH2 (0.62) | HTR4HTR3AKCNH2 | |
| SCHEMBL6306544 | 0.84 | KCNH2 (0.61) | HTR4HTR3AKCNH2 | |
| SCHEMBL6306539 | 0.84 | KCNH2 (0.61) | HTR4HTR3AKCNH2 | |
| SCHEMBL6247389 | 0.83 | KCNH2 (0.68) | HTR4HTR3AKCNH2 | |
| SCHEMBL8345408 | 0.83 | KCNH2 (0.68) | HTR4HTR3AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1620435-A1 | IMADAZOPYRIDINE COMPOUNDS HAVING 5-HT sb 4 /sb RECEPTOR AGONISTIC ACTIVITY AND 5-HT sb 3 /sb RECEPTOR ANTAGONISTIC ACTIVITY | PFIZER INC. (US) | 2006-02-01 | — | — | EP | claimed |
| US-20040266814-A1 | Imidazopyridine compounds having 5-HT4 receptor agonistic activity and 5-HT3 receptor antagonistic activity | PFIZER INC | 2004-12-30 | — | — | US | claimed |
| WO-2004094418-A1 | IMIDAZOPYRIDINE COMPOUNDS HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY AND 5-HT3 RECEPTOR ANTAGONISTIC ACTIVITY | PFIZER INC. (US) | 2004-11-04 | — | — | WO | claimed |
| US-7012080-B2 | Imidazopyridine compounds as 5-HT4 receptor agonists | PFIZER INC. (US) | 2006-03-14 | — | — | US | disclosed |
| EP-1620435-A1 | IMADAZOPYRIDINE COMPOUNDS HAVING 5-HT sb 4 /sb RECEPTOR AGONISTIC ACTIVITY AND 5-HT sb 3 /sb RECEPTOR ANTAGONISTIC ACTIVITY | PFIZER INC. (US) | 2006-02-01 | — | — | EP | disclosed |
| EP-1440071-B1 | IMIDAZOPYRIDINE COMPOUNDS AS 5-HT 4? RECEPTOR MODULATORS | PFIZER (US) | 2005-10-26 | — | — | EP | disclosed |
| US-6951867-B2 | N-substituted piperidinyl-imidazopyridine compounds as 5-HT4 receptor modulators | PFIZER INC. (US) | 2005-10-04 | — | — | US | disclosed |
| US-20040266814-A1 | Imidazopyridine compounds having 5-HT4 receptor agonistic activity and 5-HT3 receptor antagonistic activity | PFIZER INC | 2004-12-30 | — | — | US | disclosed |
| WO-2004094418-A1 | IMIDAZOPYRIDINE COMPOUNDS HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY AND 5-HT3 RECEPTOR ANTAGONISTIC ACTIVITY | PFIZER INC. (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004094418-A1 | IMIDAZOPYRIDINE COMPOUNDS HAVING 5-HT4 RECEPTOR AGONISTIC ACTIVITY AND 5-HT3 RECEPTOR ANTAGONISTIC ACTIVITY | PFIZER INC. (US) | 2004-11-04 | — | — | WO | disclosed |
| EP-1440071-A1 | IMIDAZOPYRIDINE COMPOUNDS AS 5-HT 4? RECEPTOR MODULATORS | Pfizer Japan Inc. (JP) | 2004-07-28 | — | — | EP | disclosed |
| US-20040127514-A1 | N-substituted piperidinyl-imidazopyridine compounds as 5-HT4 receptor modulators | PFIZER INC | 2004-07-01 | — | — | US | disclosed |
| US-20040122043-A1 | Imidazopyridine compounds as 5-HT4 receptor agonists | PFIZER INC | 2004-06-24 | — | — | US | disclosed |
| US-20040034226-A1 | Imidazopyridine compounds as 5-HT4 receptor modulators | UCHIDA CHIKARA (JP) | 2004-02-19 | — | — | US | disclosed |
| US-6624162-B2 | 5-HT4 receptor binding activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, Functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans. | PFIZER INC. | 2003-09-23 | — | — | US | disclosed |
| US-20030092699-A1 | Imidazopyridine compounds as 5-HT4 receptor modulators | PFIZER INC. | 2003-05-15 | — | — | US | disclosed |
| WO-2003035649-A1 | IMIDAZOPYRIDINE COMPOUNDS AS 5-HT4 RECEPTOR MODULATORS | PFIZER JAPAN INC. (JP) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092699-A1 | Imidazopyridine compounds as 5-HT4 receptor modulators | HTR4, HRH4, HRH2 | HTR4 1/4885HTR3A 28/4885KCNH2 962/4885 |
| US-20040127514-A1 | N-substituted piperidinyl-imidazopyridine compounds as 5-HT4 receptor modulators | HTR4, HRH4, HRH2 | HTR4 1/4885HTR3A 35/4885KCNH2 1390/4885 |
| US-20040266814-A1 | Imidazopyridine compounds having 5-HT4 receptor agonistic activity and 5-HT3 receptor antagonistic activity | HTR4, HRH4, GIPR | HTR4 1/4885HTR3A 11/4885KCNH2 1253/4885 |
| US-20040122043-A1 | Imidazopyridine compounds as 5-HT4 receptor agonists | HTR4, GPR4, HRH4 | HTR4 1/4885HTR3A 35/4885KCNH2 840/4885 |
| US-20040034226-A1 | Imidazopyridine compounds as 5-HT4 receptor modulators | HRH4, HTR4, HRH2 | HTR4 2/4885HTR3A 27/4885KCNH2 895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.